Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.
about
Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Long-term treatment with bosut ...... ne kinase inhibitor treatment.
@en
Long-term treatment with bosut ...... ne kinase inhibitor treatment.
@nl
type
label
Long-term treatment with bosut ...... ne kinase inhibitor treatment.
@en
Long-term treatment with bosut ...... ne kinase inhibitor treatment.
@nl
prefLabel
Long-term treatment with bosut ...... ne kinase inhibitor treatment.
@en
Long-term treatment with bosut ...... ne kinase inhibitor treatment.
@nl
P2093
P2860
P1476
Long-term treatment with bosut ...... ine kinase inhibitor treatment
@en
P2093
Chiaki Nakaseko
Kazunori Ohnishi
Koichi Miyamura
Yosuke Fujii
Yuichiro Koide
P2860
P2888
P304
P356
10.1007/S12185-017-2239-8
P577
2017-04-13T00:00:00Z